Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
Overview of attention for article published in The Lancet Diabetes & Endocrinology, September 2013
Altmetric Attention Score: 94
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (98th percentile)
-
High Attention Score compared to outputs of the same age and source (90th percentile)
Mentioned by
- news
- 8 news outlets
- 36 X users
- patent
- 4 patents
- 1 Facebook page
- guideline
- 2 clinical guideline sources
Readers on
- mendeley
- 150 Mendeley